Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00417573|
Recruitment Status : Completed
First Posted : January 1, 2007
Last Update Posted : January 1, 2007
- This is the first study, that we are aware of, that will evaluate the efficacy of IgIV in patients with IgG subclass deficiency.
- Will provide data for further collaboration in extending study to involve other immunological centers in the United States to study patients with similar disease.
|Condition or disease||Intervention/treatment||Phase|
|IgG Deficiency Infections||Drug: IV Gamunex 10%||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections|
|Study Start Date :||December 2004|
|Study Completion Date :||December 2006|
- Lab values ck'ed baseline and with each treatment, and 15 mo. visit
- Xray of Chest and sinus baseline and on 12th and last treatment
- Clinical assessment baseline, every treatment, and 15 mo.
- Patient questionnaires completed by patients, baseline, prior to each treatment, and at 15 month vist.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00417573
|United States, Missouri|
|Center for Rheumatic Disease, Allergy, Immunology|
|Kansas City, Missouri, United States, 64111|
|Principal Investigator:||Nabih I Abdou, MD, PhD||Center for Rheumatic Disease, Allergy, Immunology|